A Study to Assess the Acceptability of the Darunavir/Cobicistat (DRV/COBI) Fixed-dose Combination (FDC) Tablet in Human Immunodeficiency Virus (HIV)-1 Infected Children Aged ≥3 Years and Weighing ≥15 kg to <25 kg
Latest Information Update: 19 Sep 2023
At a glance
- Drugs Cobicistat/darunavir (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Sponsors Janssen Research & Development
Most Recent Events
- 25 Oct 2022 Status changed from recruiting to completed.
- 02 Aug 2022 Planned initiation date changed from 28 Jul 2022 to 19 Aug 2022.
- 02 Aug 2022 Status changed from not yet recruiting to recruiting.